The University of Southampton
University of Southampton Institutional Repository

Role of pregabalin in the treatment of generalized anxiety disorder

Role of pregabalin in the treatment of generalized anxiety disorder
Role of pregabalin in the treatment of generalized anxiety disorder
Generalized anxiety disorder (GAD) is a common, typically persistent, and disabling condition that is often not recognised, or treated in an evidence-based manner. Current pharmacological and psychological treatment approaches have a number of drawbacks, including a delay in onset of clinical effect, varying relative efficacy against psychological or somatic symptoms of anxiety, potentially troublesome adverse effects, and discontinuation symptoms on stopping treatment. Pregabalin is a structural analog of the inhibitory neurotransmitter gamma amino butyric acid (GABA) but is thought to exert its anxiolytic effects through binding in a state-dependent manner to the alpha-2-delta sub-unit of voltagegated calcium channels in “over-excited” pre-synaptic neurones, reducing release of excitatory neurotransmitters such as glutamate and substance P. At fixed doses of 200 mg/day or greater, it has consistent proven efficacy in acute treatment of DSM-IV-defined GAD, with some evidence of an early onset of clinical effect, and of efficacy across psychological and somatic anxiety symptom clusters. A pregabalin dosage of 450 mg/day is efficacious in the prevention of relapse. There is at present no published direct comparison with an SSRI. The current known adverse effect profile and studies in healthy volunteers together suggest that pregabalin may have some tolerability advantages over benzodiazepines and venlafaxine, at least in short-term treatment.
treatment, generalized anxiety disorder, efficacy, tolerability, pregabalin
1176-6328
185-191
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Ajel, Khalil
4cd2fee4-e3f9-4fb6-b73e-fbfd8b50b40a
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Ajel, Khalil
4cd2fee4-e3f9-4fb6-b73e-fbfd8b50b40a

Baldwin, David S. and Ajel, Khalil (2007) Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatric Disease and Treatment, 3 (2), 185-191.

Record type: Article

Abstract

Generalized anxiety disorder (GAD) is a common, typically persistent, and disabling condition that is often not recognised, or treated in an evidence-based manner. Current pharmacological and psychological treatment approaches have a number of drawbacks, including a delay in onset of clinical effect, varying relative efficacy against psychological or somatic symptoms of anxiety, potentially troublesome adverse effects, and discontinuation symptoms on stopping treatment. Pregabalin is a structural analog of the inhibitory neurotransmitter gamma amino butyric acid (GABA) but is thought to exert its anxiolytic effects through binding in a state-dependent manner to the alpha-2-delta sub-unit of voltagegated calcium channels in “over-excited” pre-synaptic neurones, reducing release of excitatory neurotransmitters such as glutamate and substance P. At fixed doses of 200 mg/day or greater, it has consistent proven efficacy in acute treatment of DSM-IV-defined GAD, with some evidence of an early onset of clinical effect, and of efficacy across psychological and somatic anxiety symptom clusters. A pregabalin dosage of 450 mg/day is efficacious in the prevention of relapse. There is at present no published direct comparison with an SSRI. The current known adverse effect profile and studies in healthy volunteers together suggest that pregabalin may have some tolerability advantages over benzodiazepines and venlafaxine, at least in short-term treatment.

Full text not available from this repository.

More information

Published date: 2007
Keywords: treatment, generalized anxiety disorder, efficacy, tolerability, pregabalin

Identifiers

Local EPrints ID: 62280
URI: https://eprints.soton.ac.uk/id/eprint/62280
ISSN: 1176-6328
PURE UUID: 4c5e644d-b0f3-423e-9568-553aa4d0c9aa

Catalogue record

Date deposited: 12 Sep 2008
Last modified: 13 Mar 2019 20:27

Export record

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×